The Roles of Genetic Mutation and Cytokines/chemokines in Immune Response and Their Association with Uveal Melanoma Patient Outcome

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Sep 27

PMID 39328513

Authors

Yong Liu

Yeen Huang

Chengzhi Zhao

Xinke Zhou

Jiachun Lu

Shenying Fang

Affiliations

Soon will be listed here.

Abstract

The impact of tumor mutations and the interplay of cytokines and chemokines on the immune response and clinical outcomes in uveal melanoma (UM) warrants further exploration. In our study, we delved into the correlation between genetic alterations and survival rates in a cohort of 188 UM patients, utilizing data from cBioPortal. We assessed the composition of immune cell populations within 80 UM tumors by examining RNA sequence-based gene expression data from The Cancer Genome Atlas (TCGA). Furthermore, we scrutinized the relationship between genetic mutations and the expression of cytokines and chemokines, as well as their influence on various immune cell subsets. Our investigation revealed a significant association between the presence of mutated GNAQ or SF3B1 genes and improved progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) when compared to patients with non-mutated counterparts. In contrast, the presence of immune response gene mutations was associated with a detrimental effect on PFS, DSS, and OS. We also observed that the expression levels of cytokines and chemokines were positively linked to the infiltration of immune killer cells and inversely related to the populations of B cells and dendritic cells. Elevated expression levels of PDCD1, TNF, IL6, CXCL9, and CXCL10 were found to be correlated with reduced OS. Intriguingly, an increase in CD8 T cell populations was associated with a poorer OS, a finding that warrants further investigation. These findings underscore the potential utility of cytokines/chemokines expression levels, immune cell subsets, and mutation status as critical biomarkers for the selection of patients who are most likely to benefit from immunotherapeutic interventions. Our research provides valuable insights that could guide the development of more targeted and effective treatment strategies for UM patients.

References

Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B . Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(7):1593806. PMC: 6527267. DOI: 10.1080/2162402X.2019.1593806. View

Hurdogan O, De Logu F, Galli F, Tuncer S, Ugolini F, Simi S . Digital Quantification of Intratumoral CD8+ T-Cells Predicts Relapse and Unfavorable Outcome in Uveal Melanoma. Cancers (Basel). 2022; 14(23). PMC: 9740732. DOI: 10.3390/cancers14235959. View

Shields C, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally D . Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127(8):989-98. DOI: 10.1001/archophthalmol.2009.208. View

Khalili J, Yu X, Wang J, Hayes B, Davies M, Lizee G . Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012; 18(16):4345-55. PMC: 3935730. DOI: 10.1158/1078-0432.CCR-11-3227. View

Kahles A, Lehmann K, Toussaint N, Huser M, Stark S, Sachsenberg T . Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell. 2018; 34(2):211-224.e6. PMC: 9844097. DOI: 10.1016/j.ccell.2018.07.001. View

Metz C, Lohmann D, Zeschnigk M, Bornfeld N . [Uveal melanoma: current insights into clinical relevance of genetic testing]. Klin Monbl Augenheilkd. 2013; 230(7):686-91. DOI: 10.1055/s-0033-1350628. View

Schumacher K, Haensch W, Roefzaad C, Schlag P . Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001; 61(10):3932-6. View

Ge Y, Tian N, Lu Y, Wu Y, Hu Q, Huang Z . Occupational cooking and risk of uveal melanoma: a meta-analysis. Asian Pac J Cancer Prev. 2012; 13(10):4927-30. DOI: 10.7314/apjcp.2012.13.10.4927. View

Armstrong R . When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014; 34(5):502-8. DOI: 10.1111/opo.12131. View

10.

Sato E, Olson S, Ahn J, Bundy B, Nishikawa H, Qian F . Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51):18538-43. PMC: 1311741. DOI: 10.1073/pnas.0509182102. View

11.

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25):2654-66. DOI: 10.1056/NEJMoa051424. View

12.

Gajewski T, Fuertes M, Spaapen R, Zheng Y, Kline J . Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2010; 23(2):286-92. PMC: 3070788. DOI: 10.1016/j.coi.2010.11.013. View

13.

Cheng F, Cho S, Lee J . Multi-gene expression-based statistical approaches to predicting patients' clinical outcomes and responses. Methods Mol Biol. 2010; 620:471-84. DOI: 10.1007/978-1-60761-580-4_16. View

14.

Shields C, Kaliki S, Furuta M, Mashayekhi A, Shields J . Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012; 32(7):1363-72. DOI: 10.1097/IAE.0b013e31824d09a8. View

15.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

16.

Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

17.

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A . Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2009; 138(4):1429-40. DOI: 10.1053/j.gastro.2009.10.057. View

18.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

19.

Pamporaki C, Prodanov T, Meuter L, Berends A, Bechmann N, Constantinescu G . Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. Eur J Cancer. 2022; 169:32-41. DOI: 10.1016/j.ejca.2022.03.032. View

20.

Mizue Terai , Shimada A, Chervoneva I, Hulse L, Danielson M, Swensen J . Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. Cancers (Basel). 2021; 13(22). PMC: 8616238. DOI: 10.3390/cancers13225749. View